Irisin in patients with nonalcoholic fatty liver disease

Metabolism: Clinical and Experimental

Volumn 63, Issue 2, 2014, Pages 207-217

  Polyzos, Stergios A ^a   Kountouras, Jannis ^a   Anastasilakis, Athanasios D ^b   Geladari, Eleni V ^c   Mantzoros, Christos S ^c  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b 424 General Army Hospital   (Greece)

^c HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Chemerin; Fibronectin type III domain containing 5; Nonalcoholic steatohepatitis; Portal inflammation; Retinol binding protein 4

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; CHEMERIN; CYTOKINE; IRISIN; LEPTIN; RETINOL BINDING PROTEIN 4; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BODY MASS; CARDIOMETABOLIC RISK; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; EXERCISE; FATTY LIVER; FEMALE; HEPATITIS; HORMONE BLOOD LEVEL; HUMAN; INSULIN RESISTANCE; LIVER BIOPSY; LIVER FUNCTION TEST; MALE; NONALCOHOLIC FATTY LIVER; OBESITY; PORTAL INFLAMMATION; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; WAIST CIRCUMFERENCE;

ALANINE TRANSAMINASE; ALKALINE PHOSPHATASE; ALP; ALT; ASPARTATE TRANSAMINASE; AST; BMI; BODY MASS INDEX; CHEMERIN; FIBRONECTIN TYPE III DOMAIN CONTAINING; FIBRONECTIN TYPE III DOMAIN CONTAINING 5; FNDC; GAMMA-GLUTAMYL TRANSFERASE; GGT; HDL-C; HIGH-DENSITY LIPOPROTEIN CHOLESTEROL; HOMA-IR; HOMEOSTATIC MODEL OF ASSESSMENT INSULIN RESISTANCE; INSULIN RESISTANCE; IR; LDL-C; LETO; LONG EVANS TOKUSHIMA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METABOLIC SYNDROME; METS; NAFL; NAFLD; NAFLD ACTIVITY SCORE; NAS; NASH; NON-ALCOHOLIC FATTY LIVER DISEASE; NONALCOHOLIC STEATOHEPATITIS; OLETF; OTSUKA LONG-EVANS TOKUSHIMA FATTY; PORTAL INFLAMMATION; QUANTITATIVE INSULIN SENSITIVITY CHECK INDEX; QUICKI; RBP; RETINOL-BINDING PROTEIN; RETINOL-BINDING PROTEIN-4; SIMPLE NONALCOHOLIC FATTY LIVER; T2DM; TYPE 2 DIABETES MELLITUS; WAIST CIRCUMFERENCE.; WC;

ADIPOKINES; ADIPONECTIN; ADULT; AGED; BIOLOGICAL MARKERS; BODY MASS INDEX; CASE-CONTROL STUDIES; CHEMOKINES; FATTY LIVER; FEMALE; FIBRONECTINS; HUMANS; INFLAMMATION; INSULIN RESISTANCE; LEPTIN; MALE; MIDDLE AGED; OBESITY; PORTAL VEIN; RETINOL-BINDING PROTEINS, PLASMA; RISK FACTORS; SEVERITY OF ILLNESS INDEX; THINNESS;

EID: 84892672291     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2013.09.013     Document Type: Article

References (50)

1. G. Vernon, A. Baranova, and Z.M. Younossi Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults Aliment Pharmacol Ther 34 3 2011 274 285
2. S.A. Polyzos, J. Kountouras, and C. Zavos Nonalcoholic fatty liver disease: the pathogenetic roles of insulin resistance and adipocytokines Curr Mol Med 9 3 2009 299 314
3. M. Jacobs, M.M. van Greevenbroek, and C.J. van der Kallen et al. The association between the metabolic syndrome and alanine amino transferase is mediated by insulin resistance via related metabolic intermediates (the Cohort on Diabetes and Atherosclerosis Maastricht [CODAM] study) Metabolism 60 7 2011 969 975
4. S. Bluher, E. Molz, and S. Wiegand et al. Body mass index, waist circumference, and waist-to-height ratio as predictors of cardiometabolic risk in childhood obesity depending on pubertal development J Clin Endocrinol Metab 98 8 2013 3384 3393
5. M.V. Machado, and H. Cortez-Pinto Non-invasive diagnosis of non-alcoholic fatty liver disease. A critical appraisal J Hepatol 58 5 2013 1007 1019
6. S.A. Polyzos, J. Kountouras, and C. Zavos et al. Nonalcoholic fatty liver disease: multimodal treatment options for a pathogenetically multiple-hit disease J Clin Gastroenterol 46 4 2012 272 284
7. V. Ratziu, S. Bellentani, and H. Cortez-Pinto et al. A position statement on NAFLD/NASH based on the EASL 2009 special conference J Hepatol 53 2 2010 372 384
8. N. Chalasani, Z. Younossi, and J.E. Lavine et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association Hepatology 55 6 2012 2005 2023
9. B.K. Pedersen A muscular twist on the fate of fat N Engl J Med 366 16 2012 1544 1545
10. P. Bostrom, J. Wu, and M.P. Jedrychowski et al. A PGC1-alpha-dependent myokine that drives brown-fat-like development of white fat and thermogenesis Nature 481 7382 2012 463 468
11. J.Y. Huh, G. Panagiotou, and V. Mougios et al. FNDC5 and irisin in humans: I Predictors of circulating concentrations in serum and plasma and II. mRNA expression and circulating concentrations in response to weight loss and exercise Metabolism 61 12 2012 1725 1738
12. H.S. Moon, F. Dincer, and C.S. Mantzoros Pharmacological concentrations of irisin increase cell proliferation without influencing markers of neurite outgrowth and synaptogenesis in mouse H19-7 hippocampal cell lines Metabolism 62 8 2013 1131 1136
13. J.N. Fain, J.M. Company, and F.W. Booth et al. Exercise training does not increase muscle FNDC5 protein or mRNA expression in pigs Metabolism 62 10 2013 1503 1511
14. A.G. Swick, S. Orena, and A. O'Connor Irisin levels correlate with energy expenditure in a subgroup of humans with energy expenditure greater than predicted by fat free mass Metabolism 62 8 2013 1070 1073
15. S.A. Polyzos, J. Kountouras, and K. Shields et al. Irisin: a renaissance in metabolism? Metabolism 62 8 2013 1037 1044
16. D.E. Kleiner, E.M. Brunt, and M. Van Natta et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease Hepatology 41 6 2005 1313 1321 (Pubitemid 40770284)
17. S.A. Polyzos, J. Kountouras, and A. Papatheodorou et al. Helicobacter pylori infection in patients with nonalcoholic fatty liver disease Metabolism 62 1 2013 121 126
18. M. Bluher, A.M. Brennan, and T. Kelesidis et al. Total and high-molecular weight adiponectin in relation to metabolic variables at baseline and in response to an exercise treatment program: comparative evaluation of three assays Diabetes Care 30 2 2007 280 285 (Pubitemid 46198331)
19. L. Qi, A. Doria, and J.E. Manson et al. Adiponectin genetic variability, plasma adiponectin, and cardiovascular risk in patients with type 2 diabetes Diabetes 55 5 2006 1512 1516 (Pubitemid 44195395)
20. C. Heidemann, Q. Sun, and R.M. van Dam et al. Total and high-molecular-weight adiponectin and resistin in relation to the risk for type 2 diabetes in women Ann Intern Med 149 5 2008 307 316
21. S.A. Shea, M.F. Hilton, and C. Orlova et al. Independent circadian and sleep/wake regulation of adipokines and glucose in humans J Clin Endocrinol Metab 90 5 2005 2537 2544 (Pubitemid 40686288)
22. C.S. Mantzoros, A.D. Liolios, and N.A. Tritos et al. Circulating insulin concentrations, smoking, and alcohol intake are important independent predictors of leptin in young healthy men Obes Res 6 3 1998 179 186 (Pubitemid 128679659)
23. K.M. Choi, M. Yannakoulia, and M.S. Park et al. Serum adipocyte fatty acid-binding protein, retinol-binding protein 4, and adiponectin concentrations in relation to the development of the metabolic syndrome in Korean boys: a 3-y prospective cohort study Am J Clin Nutr 93 1 2011 19 26
24. Chamberland JP, Berman RL, Aronis KN, et al. Chemerin is expressed mainly in pancreas and liver, is regulated by energy deprivation and lacks day/night variation in humans. Eur J Endocrinol 2013;10.164(4):453-62.
25. H.J. Zhang, X.F. Zhang, and Z.M. Ma et al. Irisin is inversely associated with intrahepatic triglyceride contents in obese adults J Hepatol 59 3 2013 557 562
26. M. Gleeson, N.C. Bishop, and D.J. Stensel et al. The anti-inflammatory effects of exercise: mechanisms and implications for the prevention and treatment of disease Nat Rev Immunol 11 9 2011 607 615
27. S.A. Polyzos, J. Kountouras, and C. Zavos Nonlinear distribution of adiponectin in patients with nonalcoholic fatty liver disease limits its use in linear regression analysis J Clin Gastroenterol 44 3 2010 229 230
28. S.A. Polyzos, J. Kountouras, and C. Zavos et al. Adipocytokines in insulin resistance and non-alcoholic fatty liver disease: the two sides of the same coin Med Hypotheses 74 6 2010 1089 1090
29. H.S. Moon, M. Dalamaga, and S.Y. Kim et al. Leptin's role in lipodystrophic and nonlipodystrophic insulin-resistant and diabetic individuals Endocr Rev 34 3 2013 377 412
30. S.A. Polyzos, J. Kountouras, and C. Zavos et al. The potential adverse role of leptin resistance in nonalcoholic fatty liver disease: a hypothesis based on critical review of the literature J Clin Gastroenterol 45 1 2011 50 54
31. Y.K. Choi, M.K. Kim, and K.H. Bae et al. Serum irisin levels in new-onset type 2 diabetes Diabetes Res Clin Pract 100 1 2013 96 101
32. J.J. Liu, M.D. Wong, and W.C. Toy et al. Lower circulating irisin is associated with type 2 diabetes mellitus J Diabetes Complications 27 4 2013 365 369
33. J.M. Moreno-Navarrete, F. Ortega, and M. Serrano et al. Irisin is expressed and produced by human muscle and adipose tissue in association with obesity and insulin resistance J Clin Endocrinol Metab 98 4 2013 E769 E778
34. K. Hojlund, and P. Bostrom Irisin in obesity and type 2 diabetes J Diabetes Complications 27 4 2013 303 304
35. A. Stengel, T. Hofmann, and M. Goebel-Stengel et al. Circulating levels of irisin in patients with anorexia nervosa and different stages of obesity - correlation with body mass index Peptides 2013 39125 39130
36. K.H. Park, L. Zaichenko, and M. Brinkoetter et al. Circulating irisin in relation to insulin resistance and the metabolic syndrome J Clin Endocrinol Metab 2013 10.1210/jc.2013-2373
37. I. Gouni-Berthold, H.K. Berthold, and J.Y. Huh et al. Effects of lipid-lowering drugs on irisin in human subjects in vivo and in human skeletal muscle cells ex vivo PLoS One 8 9 2013 e72858
38. M.D. Roberts, D.S. Bayless, and J.M. Company et al. Elevated skeletal muscle irisin precursor FNDC5 mRNA in obese OLETF rats Metabolism 62 8 2013 1052 1056
39. S.A. Polyzos, K.A. Toulis, and D.G. Goulis et al. Serum total adiponectin in nonalcoholic fatty liver disease: a systematic review and meta-analysis Metabolism 60 3 2011 313 326
40. F. Ziemke, and C.S. Mantzoros Adiponectin in insulin resistance: lessons from translational research Am J Clin Nutr 91 1 Suppl 1 2010 258 261
41. P. Pisto, O. Ukkola, and M. Santaniemi et al. Plasma adiponectin - an independent indicator of liver fat accumulation Metabolism 60 11 2011 1515 1520
42. A. Sahin-Efe, F. Katsikeris, and C.S. Mantzoros Advances in adipokines Metabolism 61 12 2012 1659 1665
43. O.P. Hamnvik, X. Liu, and M. Petrou et al. Soluble leptin receptor and leptin are associated with baseline adiposity and metabolic risk factors, and predict adiposity, metabolic syndrome, and glucose levels at 2-year follow-up: the Cyprus Metabolism Prospective Cohort Study Metabolism 60 7 2011 987 993
44. J.A. Seo, N.H. Kim, and S.Y. Park et al. Serum retinol-binding protein 4 levels are elevated in non-alcoholic fatty liver disease Clin Endocrinol (Oxf) 68 4 2008 555 560 (Pubitemid 351388698)
45. H. Wu, W. Jia, and Y. Bao et al. Serum retinol binding protein 4 and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus Diabetes Res Clin Pract 79 2 2008 185 190
46. N. Alkhouri, R. Lopez, and M. Berk et al. Serum retinol-binding protein 4 levels in patients with nonalcoholic fatty liver disease J Clin Gastroenterol 43 10 2009 985 989
47. C. Cengiz, Y. Ardicoglu, and S. Bulut et al. Serum retinol-binding protein 4 in patients with nonalcoholic fatty liver disease: does it have a significant impact on pathogenesis? Eur J Gastroenterol Hepatol 22 7 2010 813 819
48. M. Kukla, K. Zwirska-Korczala, and M. Hartleb et al. Serum chemerin and vaspin in non-alcoholic fatty liver disease Scand J Gastroenterol 45 2 2010 235 242
49. Y. Yilmaz, O. Yonal, and R. Kurt et al. Serum levels of omentin, chemerin and adipsin in patients with biopsy-proven nonalcoholic fatty liver disease Scand J Gastroenterol 46 1 2011 91 97
50. J.L. Rourke, H.J. Dranse, and C.J. Sinal Towards an integrative approach to understanding the role of chemerin in human health and disease Obes Rev 14 3 2013 245 262 Diseases